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A B S T R A C T   
Background: Asthma prevalence, morbidity, and mortality disproportionately impact African American/Black 
(AA/B) and Hispanic/Latinx (H/L) communities. Adherence to daily inhaled corticosteroid (ICS), recommended 
by asthma guidelines in all but the mildest cases of asthma, is generally poor. As-needed ICS has shown promise 
as a patient-empowering asthma management strategy, but it has not been rigorously studied in AA/B or H/L 
patients or in a real-world setting. 
Design and Aim 
The PeRson EmPowered Asthma RElief (PREPARE) Study is a randomized, open-label, pragmatic study which 
aims to assess whether a patient-guided, reliever-triggered ICS strategy called PARTICS (Patient-Activated 
Reliever-Triggered Inhaled CorticoSteroid) can improve asthma outcomes in AA/B and H/L adult patient pop-
ulations. In designing and implementing the study, the PREPARE research team has relied heavily on advice from 
AA/B and H/L Patient Partners and other stakeholders. 
Methods 
PREPARE is enrolling 1200 adult participants (600 AA/Bs, 600H/Ls) with asthma. Participants are randomized 
to PARTICS + Usual Care (intervention) versus Usual Care (control). Following a single in-person enrollment 
visit, participants complete monthly questionnaires for 15 months. The primary endpoint is annualized asthma 
exacerbation rate. Secondary endpoints include asthma control; preference-based quality of life; and days lost 
from work, school, or usual activities. 
Discussion 
The PREPARE study features a pragmatic design allowing for the real-world assessment of a patient-centered, 
reliever-triggered ICS strategy in AA/B and H/L patients. Outcomes of this study have the potential to offer 
powerful evidence supporting PARTICS as an effective asthma management strategy in patient populations that 
suffer disproportionately from asthma morbidity and mortality.   
1. Introduction 
In the United States, 25 million people (19 million adults) have 
asthma, which annually accounts for 1.8 million emergency department 
(ED) visits, 9.8 million clinic visits, 189,000 hospitalizations [1], and 
annual costs totaling over $80 billion [2]. Nearly half of adults with 
asthma report experiencing at least one asthma exacerbation annually 
[1]. Asthma exacerbations result in significant morbidity and mortality, 
with over 3400 annual asthma-attributed deaths [1]. Additionally, 
asthma exacerbations drive a large portion of asthma-related health care 
costs [2–4]. 
African American/Black (AA/B) and Hispanic/Latinx (H/L) pop-
ulations bear a disproportionate share of asthma morbidity and mor-
tality [1,5]. When compared with Caucasians, asthma prevalence is 35% 
higher in AA/Bs and approximately 100% higher in H/Ls [1,6–8]. When 
adjusted for prevalence, relative to Caucasians, AA/Bs and H/Ls 
experience higher rates of asthma-related ED visits and hospitalizations 
[9–14] and approximately double the death rate [1,15]. 
The 2007 National Asthma Education and Prevention Program 
(NAEPP) guidelines recommend regular use of an inhaled corticosteroid 
(ICS) in all but the mildest cases [16]. Unfortunately, implementation of 
NAEPP guidelines has been inadequate [17], especially for AA/B and H/ 
L patients [18,19]. Clinicians may not prescribe ICS, and patients may 
not adhere to daily ICS use when prescribed. Patients fill on average only 
3 months’ worth of asthma controller therapies (such as ICS) per year 
[20–23]. Low adherence to daily ICS regimens may reflect patients’ 
experience of the episodic nature of asthma symptoms and perceived 
need for therapy [24]. Unfortunately, while intensive programs to 
improve adherence may have some effect, they remain expensive and 
difficult to scale-up [25]. 
Difficulties with adherence to regular ICS has led to investigations of 
as-needed ICS. A study of as-needed ICS triggered by symptoms in 
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patients with mild asthma showed that exacerbation rates were no 
different between those who used symptom-based versus regular ICS 
[26]. Subsequently, studies of ICS use triggered by short-acting β2- 
agonist (SABA) use showed similar results [27,28]. In all of these 
studies, as-needed ICS use resulted in significantly less total ICS expo-
sure. Subsequent studies with combination ICS and the long-acting β2- 
agonist (LABA) formoterol have produced similar findings [29–32]. 
However, studies of a reliever-triggered ICS strategy have not been 
conducted in AA/B or H/L populations and, except for one [32], have 
not been conducted in real-world settings. 
An as-needed ICS strategy (in addition to regular controller therapy 
or not) has several potential real-world benefits, including mitigating 
adherence-related challenges and reducing burden on healthcare pro-
fessionals, which may reduce implementation barriers. We therefore 
investigated a reliever-triggered ICS strategy, which we call PARTICS 
(Patient-Activated Reliever-Triggered Inhaled CorticoSteroid), in which 
the patient uses ICS each time he or she uses a reliever medication such 
as SABA (e.g., albuterol). In the PeRson EmPowered Asthma RElief 
(PREPARE) study, funded by the Patient-Centered Outcomes Research 
Institute (PCORI), our aim is to assess whether the PARTICS strategy can 
improve asthma outcomes in AA/B and H/L adult patient populations in 
a real-world setting. 
2. Study procedures 
2.1. Study overview and goal 
The PREPARE study is a randomized, open-label, pragmatic trial in 
AA/B and H/L adults with asthma. The goal is to determine whether 
PARTICS improves outcomes important to patients, health care pro-
fessionals, and the health care system in AA/B and H/L populations 
disproportionately impacted by asthma. The primary endpoint of the 
trial is the annualized rate of asthma exacerbations requiring systemic 
steroid therapy or hospitalization. This endpoint was selected due to its 
relevance and importance to all stakeholders involved in the planning of 
this study, including AA/B and H/L adults with asthma and/or care-
givers of individuals with asthma (our “patient partners”), patient ad-
vocates (members of patient advocacy societies), asthma researchers, 
healthcare professionals, and health system and policy leaders. 
2.2. Protocol development 
The PREPARE protocol was designed to adhere to PCORI Method-
ology Standards [33] with regards to patient centeredness, data integrity 
and analytical rigor; and as a pragmatic trial, as judged by PRagmatic 
Explanatory Continuum Indicator Summary (PRECIS) criteria [34]. In 
developing the PREPARE protocol, the investigators consulted with 
numerous stakeholders, including our patient partners, health care 
professionals, leaders of professional societies, patient advocacy groups, 
health policy leaders, pharmacists, and representatives of pharmaceu-
tical companies—all of whom offered broad input in study design, 
implementation, and commitments for dissemination. 
In the initial stages of protocol development, conference calls with 
patient partners and other stakeholders were held at least monthly to 
develop the study materials and processes and ensure that PREPARE 
remained patient-centered and of low burden to study participants. 
Patient partners and stakeholders are an integral part of the team and 
have been involved in all aspects of planning and decision-making, 
throughout the entire study (Table 1). 
2.3. Study participants and sites 
PREPARE is enrolling 1200 adult (age 18–75) participants with 
asthma, who self-identify as AA/B (n = 600) or H/L (n = 600). 
Recruitment began in November 2017 and was completed in March 
2020. Participants are recruited from 19 clinical organizations 
(Supplement 1), representing a diverse range in practice size, health 
system type, geographic distribution, and specialty (allergy/immu-
nology, pulmonology, and family medicine/internal medicine, with the 
majority being primary care clinics). The American Academy of Family 
Physicians National Research Network (AAFP NRN) serves as our site 
coordinating center, managing site training and ongoing site support. 
Enrolled participants are centrally randomized 1:1 to one of two 
study arms: PARTICS + Usual Care (intervention) versus Usual Care 
(control). Planned duration of follow-up is 15 months. Participants 
attend one in-person visit to enroll in the study, provide baseline de-
mographics, and view pre-recorded videos which provide a detailed 
overview of the PREPARE study, education on asthma, and for those in 
the intervention arm, instructions on how to use PARTICS. Following the 
single in-person enrollment visit, all participants receive one follow-up 
telephone call within the first month after enrollment to ensure com-
fort filling out the monthly questionnaires and to reinforce study pro-
cedures. Participants then complete study questionnaires each month 
for 15 months (Fig. 1). Data collected from these 15 monthly ques-
tionnaires will be used to determine patient outcomes. Participants are 
compensated 50 dollars for the enrollment visit, and 20 dollars for each 
completed questionnaire. Randomization, patient intake, informed 
consent, baseline data collection, and monthly survey data collection are 
completed using the Patient Engaged Electronic Reporting System 
(PEERS®), a Health Insurance Portability and Accountability Act 
(HIPAA)-compliant electronic data capture and study management 
system developed by the University of Colorado Department of Family 
Medicine. 
2.4. Intervention: PARTICS 
Participants randomized to the PARTICS intervention are provided a 
pressurized metered-dose inhaler (pMDI) containing the ICS beclome-
thasone dipropionate hydrofluoroalkane (HFA) 80 μg (QVAR® prior to 
December 2018, QVAR® RediHaler™ thereafter; Teva Respiratory, 
LLC), and are instructed to use one puff of ICS for every puff of reliever 
inhaler used as needed, and 5 puffs of ICS for every reliever nebulizer 
treatment used as needed. Participants view a video, co-developed with 
our patient partners, that gives education on asthma and explains how 
and why to use the PARTICS medications (video available upon 
request). We provide a medication pouch for the participants’ PARTICS 
inhalers, and a Velcro® band to attach the ICS and reliever inhalers to 
one another. 
2.5. Control 
Participants randomized to the Usual Care arm do not have any 
required changes to their asthma therapy. All participants watch an 
enrollment video concerning asthma (for participants in the control arm, 
PARTICS-related instructions are removed). To maintain a similar 
Table 1 
Frequency of in-person meetings and conference calls for various stakeholder 







Patient Partners Up to bi-monthly Monthly Monthly 
Patient Advocates Quarterly Quarterly Monthly 
Other Professional 
Stakeholders 
Up to monthly Quarterly Quarterly 
Executive Committeea Monthly Monthly Monthly  
a The Executive Committee governs the study and is comprised of in-
vestigators and representatives of stakeholder groups, including AA/B patient 
partners, H/L patient partners, patient advocates, healthcare professionals, 
professional societies, health policy leaders, and clinical trials experts. 
b To contribute to data analysis, stakeholders listed will see preliminary data 
tables and be involved in discussions of implications of results. 
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degree of engagement with participants in the intervention versus the 
control arm, we have standardized communications and intensity of 
contact as much as possible. When an additional point of contact with 
the PARTICS group was required (e.g., sending out new beclomethasone 
inhalers due to the changeover to QVAR® RediHaler™), we added a 
point of contact with the control group as well (e.g., sending out new 
medication pouches and reminding participants to have their reliever 
medication with them at all times). 
2.6. Adaptive protocol modifications 
In the early stages of PREPARE, we noticed that participant adher-
ence to the PARTICS intervention (which is self-reported in the monthly 
questionnaires) was suboptimal in those participants using nebulized 
reliever therapy. Of these participants, 72% reported using concomitant 
ICS with their nebulized reliever all or most of the time. Furthermore, 
while the PARTICS intervention is 5 puffs of ICS with every rescue 
nebulization, only 20% of participants reported using 4–5 puffs, and 
70% reported using 1–2 puffs. In consultation with patient partners and 
stakeholders, we made adaptive modifications to the protocol and the 
enrollment videos to reinforce the PARTICS strategy with participants in 
the intervention arm. PARTICS instructions were added to a splash 
screen at the end of each monthly survey, emphasizing the ratios of 1:1 
ICS to reliever inhaler and 5:1 ICS to reliever nebulization. Participants 
in the intervention arm receive a magnet printed with the PARTICS in-
structions, and quarterly text messages reminding them of the PARTICS 
strategy. Finally, those who report using a nebulizer receive a second 
QVAR® and a Velcro® pouch (used to attach the QVAR® to the nebu-
lizer) equipped with a PREPARE trial sticker as a visual reminder. After 
these adherence interventions, 82% of nebulized rescue therapy users 
now report using concomitant ICS all or most of the time, and 63% 
report using 4–5 puffs. 
These additional reminders and points of contact with the inter-
vention group were balanced with additional reminders and points of 
contact with the control group. A splash screen message was added to 
each monthly survey reminding control participants to use their daily 
asthma controller medications even in the absence of asthma symptoms. 
Participants in the control arm receive a magnet with a message 
reminding them to keep their reliever inhaler with them at all times and 
receive quarterly text messages reminding them to take their asthma 
medicines every day. 
2.7. Standardizing usual care 
In order to reduce variation in asthma management across study 
sites, all clinicians enrolling participants into either the intervention or 
the control arm were required to complete the educational component of 
the Asthma IQ asthma management system [35], either online or by 
attending an in-person presentation. The Asthma IQ system was jointly 
developed by the American Academy of Allergy, Asthma and Immu-
nology (AAAAI) and the American Academy of Family Physicians 
(AAFP). The educational component takes approximately 20 min to 
complete and reviews the existing NAEPP Expert Panel Report-3 [36] 
guidelines for diagnosis and management of asthma. 
2.8. Study endpoints and assessments 
Primary and secondary study endpoints were determined with all 
stakeholders. They are outlined in Table 2. In consideration of mini-
mizing the burden to study participants and investigators, all data are 
collected via monthly questionnaires, completed by the study partici-
pants either online (via smartphone, desktop or laptop), by phone 
interview or by mail. The questionnaires require approximately 10 min 
to complete. 
2.9. Primary endpoint 
The primary endpoint of the trial is the annualized asthma exacer-
bation rate which, as mentioned previously, was selected based on input 
from our patient partners and other stakeholders. In this study, an 
asthma exacerbation is defined as an incidence of asthma worsening that 
requires 72 h or more of oral or parenteral steroids, or hospitalization. 
An ED visit or urgent care visit without receipt of at least 72 h of oral or 
parenteral steroids is not considered an exacerbation. 
Possible exacerbations are captured by participant self-report via a 
monthly Asthma Exacerbation Questionnaire (AEQ; Supplement 2). 
These self-reported events (possible asthma exacerbations) are verified 
in the Electronic Health Record (EHR) or, if necessary, by participant 
telephone interview. All possible asthma exacerbation events are adju-
dicated by a group of clinicians blinded to participant randomization 
status, based on pre-specified rules for adjudication, using all sources of 
data available. Only the verified and adjudicated asthma exacerbations 
will be included in the data analyses. 
2.10. Secondary endpoints 
The secondary endpoints are level of asthma control; preference- 
based quality of life; and days lost from work, school or usual activ-
ities. All secondary endpoints are assessed at baseline and then monthly 
Fig. 1. PREPARE study design. 
AA/B: African American/Black; H/L: Hispanic/Latinx. 
Table 2 
Study endpoints and related assessments.  
Primary endpoint Assessment 
Asthma exacerbation rate 
(annualized) 
Self-reported via monthly Asthma Exacerbation 
Questionnaire (AEQ), then verified and adjudicated 
Secondary endpoints Assessments 
Asthma control Asthma Control Test (ACT), assessed at baseline 
and monthly 
Preference-based quality of 
life 
Asthma Symptom Utility Index (ASUI), assessed at 
baseline and monthly 
Days lost from work, school, 
or usual activities 
Self-reported via monthly questionnaire  
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for 15 months. 
Asthma control is assessed using the Asthma Control Test (ACT), 
which is a patient self-administered tool for assessing level of asthma 
control [37]. The ACT is a validated, 5-item questionnaire that assesses 
asthma symptoms, rescue medication use, daily functioning, and overall 
perception of asthma control, with a 4-week recall. Scores on each item 
range from 1 to 5 and the total score ranges from 5 to 25. An ACT score 
> 19 indicates well-controlled asthma. 
Preference-based quality of life is assessed using the Asthma Symp-
tom Utility Index (ASUI). The ASUI is a validated, 10-item questionnaire 
designed to assess four asthma symptoms (cough, wheeze, dyspnea, and 
nocturnal awakening) and side effects from asthma medications over a 
2-week recall period [38]. The frequency and severity of each item are 
assessed on a 4-point Likert scale. The items are then weighted ac-
cording to patient preferences, and the summary score is a continuous 
scale ranging from 0 (worst possible symptoms) to 1 (no symptoms). 
Data regarding days lost from work, school, and usual activities are 
collected using a validated questionnaire developed and utilized as part 
of the National Health Interview Survey (NHIS) [39]. Study participants 
who do not work or go to school are asked about days they are unable to 
carry out usual activities due to asthma. 
Several important covariates are also assessed, as detailed in the 
Statistical Analysis section. Two of these, fractional exhaled nitric oxide 
(FeNO) and blood eosinophils, were added as assessments as an adaptive 
modification to the study protocol, in response to the increased focus on 
asthma phenotyping and biomarker analysis. FeNO is analyzed at 
baseline using a NIOX® device (generously provided by Circassia 
Limited), which non-invasively measures the amount of nitric oxide in 
exhaled breath. Blood eosinophils are analyzed via complete blood 
count (CBC) with differential at baseline, if the participant agrees to a 
blood draw. If not, a historic blood eosinophil measurement value 
within a year prior to baseline may be used. 
2.11. Developing the protocol 
We conducted a 3-month pilot study, supported by PCORI, to test the 
feasibility of the larger pragmatic PREPARE trial, and to use the results 
to improve PREPARE’s protocol. We enrolled 16 AA/B and 17H/L par-
ticipants from four sites that represented the geographic, health system 
and practice size diversity of the 19 PREPARE study sites. Participants 
had a single enrollment visit, viewed instructional videos and then 
answered monthly questionnaires at Months 1, 2, and 3; they also 
underwent qualitative phone interviews at 1, 6, and 12 weeks. The key 
findings of the pilot study, which have been detailed previously [40], 
were that questionnaire completion was suboptimal (60–70% completed 
within 15 days) and that there were gaps in understanding of the asthma 
medication terminology used in the questionnaires. These 33 partici-
pants did not enroll in the full PREPARE trial and are not included in the 
1200 PREPARE participants. 
A face-to-face meeting was held with our patient partners, other 
stakeholders and the operations group to discuss strategies to improve 
survey completion rates and understanding of inhaler terminology, 
without sacrificing the pragmatic nature of the study. We shortened the 
survey; incentivized timely survey response with a monthly lottery for a 
$100 prize (except in Florida where this is prohibited); provided the 
option of one-click access to surveys (no log-in required); added re-
minders using the PEERS® system via text message, phone message and 
email; and reinforced the importance of filling out the monthly surveys 
during the follow-up telephone call during Month 1. Because we learned 
that participants use many different terms for their inhalers, and might 
not recognize the terms “reliever”, “rescue”, “controller”, or “mainte-
nance”, we ask participants at baseline what names they use for their 
inhalers, and then personalize their surveys by referring to their inhalers 
by those names. 
2.12. Accommodations for low literacy 
To ensure that literacy or language barriers do not interfere with trial 
recruitment or data collection, all written trial material is available in 
English or Spanish and was designed for a low-literacy audience. For 
those with difficulty reading, the investigators have made available, if 
needed, oral materials for consent, video-based introductory in-
structions (English: https://youtu.be/4XXOW3I4aOg; Spanish: 
https://youtu.be/4IsW5N7kOno), and in-person telephone-based 
monthly survey completion (all in both English and Spanish). Videos 
contain members of the ethnic group with which the participant self- 
identifies. 
2.13. Participant eligibility 
Due to their stringent eligibility criteria, efficacy trials generally 
represent only about 5% of adult patients with asthma [41,42]. In 
contrast, we have set broad eligibility criteria (Table 3), including 
allowing enrollment of past or current smokers. We do exclude patients 
Table 3 
Eligibility criteria.  
Inclusion criteria Exclusion criteria  
• Physician-diagnosed asthma for at least 1 year  
• Age 18–75 years  
• African American/Black or Hispanic/Latinx based on self-identification  
• Ability to provide informed consent  
• Clinical history consistent with asthma for >1 year  
• Prescribed daily ICS with or without additional maintenance therapies 
• ACT score of ≤19 OR a patient-reported history of ≥1 asthma exacer-
bation in the past year requiring systemic corticosteroid use  
• Life expectancy <1 year  
• Known allergy to beclomethasone dipropionate  
• Chronic Obstructive Pulmonary Disease (COPD) or other chronic lung disease other than asthma, 
with the exception of the following:  
• Diagnosis of COPD in a never smoker without any other lung disease or any other disease that 
might cause airway obstruction  
• Diagnosis of COPD in a former smoker with normal pulmonary function tests (PFTs)a after the 
patient quit smoking  
• Diagnosis of COPD in a current smoker with normal PFTsa in the past 24 months  
• Diagnosis of COPD in a current or former smoker with obstruction on PFTs, but normal diffusing 
capacity in the past 24 months AND demonstrated forced expiratory volume in one second (FEV1) 
reversibility to bronchodilator of 12% or more at any time  
• Asthma exacerbation in the past month requiring use of systemic corticosteroid; visit to the doctor’s 
office, ED or urgent care; or overnight hospitalization  
• Regular systemic corticosteroid use (daily or every other day) for any reason  
• Use of biologics for asthma (injection or infusion), unless the patient has been on a stable dose of a 
biologic for at least 6 months AND:  
• Had an asthma exacerbation at least 2 months after starting the biologic, OR  
• Has a current ACT score of ≤19  
• Bronchial thermoplasty within the past 6 months  
• Another person living in the same household already enrolled in the study  
a Normal PFTs defined as: FEV1 > 80% predicted, FEV1/forced vital capacity (FVC) ≥70%, and diffusing capacity for carbon monoxide (DLCO) ≥80% predicted. 
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with known Chronic Obstructive Pulmonary Disease (COPD), unless 
they meet the lung function and smoking history criteria outlined in 
Table 3. Since the PARTICS strategy is patient-activated, and repeated 
observation of the strategy in a household might lead to adopting 
PARTICS behaviors, we do not enroll more than one study participant 
per household. 
Since the primary outcome of the study is asthma exacerbations, we 
enrolled patients at risk of exacerbation by requiring that participants 
have either poorly controlled asthma (ACT score of ≤19) or a history of 
at least one asthma exacerbation requiring systemic corticosteroid in the 
past year. 
2.14. Concomitant asthma medications 
In keeping with the pragmatic nature of this study, all participants in 
both study arms continue their current asthma medications after 
enrollment and for the duration of the study. With the exception of 
regular oral corticosteroid (OCS), all other asthma controller therapies 
are permitted. Patients on biologics may be eligible for the study if they 
have been on a stable dose for at least 6 months and either had an 
exacerbation within the last year but no earlier than 2 months after 
starting the biologic or are still symptomatic (ACT score ≤ 19). Clini-
cians are permitted to modify the participant’s asthma medication 
regimen as they see fit. 
2.15. Management of risks to human participants 
While previous studies have indicated that the PARTICS strategy 
reduces ICS exposure [26–28], it is possible that participants assigned to 
the PARTICS group may experience increased ICS exposure, particularly 
in the short-term. Participants are monitored for excess ICS use (defined 
as requesting ≥3 QVAR® refills in 1 month). All participants are 
informed of potential side effects of ICS and told to report them to their 
healthcare professional and are also advised to rinse their mouth with 
water after each ICS dose. 
Due to the pragmatic nature of this study, non-serious adverse events 
are not systematically monitored. However, serious adverse events are 
monitored and, if study-related, reported to the principal investigator 
(PI) as soon as they occur, and to the central Investigational Review 
Board (IRB) within 5 working days. A serious adverse event is defined as 
any event that results in death, hospitalization, persistent/significant 
disability, or congenital anomaly/birth defect; or is otherwise life- 
threatening. An independent safety officer who has no involvement in 
the PREPARE trial reviews safety data in a blinded manner (death and 
asthma-related hospitalization data are unblinded) twice annually. 
This study is being carried out in accordance with The Declaration of 
Helsinki. Informed consent is obtained for all participants, and partici-
pant privacy rights are rigorously observed. The study protocol was 
approved by the Partners Healthcare IRB and was approved by IRBs at 
all participating sites via reliant review. 
3. Statistical analysis 
3.1. Overview 
Statistical analysis is performed at the Statistical Data Coordinating 
Center at Duke Clinical Research Institute (DCRI), using SAS statistical 
software Version 9.4 or higher (SAS Institute Inc., Cary, NC). Data from 
PEERS® are transferred to DCRI for analysis, a process which was tested 
in the above-mentioned pilot study. 
In the final analysis, all major treatment comparisons between the 
randomized groups will be performed using the intention-to-treat (ITT) 
population. The ITT population will exclude 19 participants from one 
study site that did not comply with protocol entry criteria and study 
procedures and was closed. Participants in the ITT population will be 
analyzed according to their randomized treatment arm. All randomized 
participants are included in the safety analysis. 
Statistical comparison by treatment groups in the primary analysis 
will be performed using two-sided significance tests. A significance level 
of 0.05 will determine statistical significance for the primary analysis. If 
the analysis of the primary endpoint does not yield a p-value <0.05, the 
subgroup analyses of the primary endpoint data and the analyses of the 
secondary endpoints will all be considered exploratory. 
3.2. Sample size and power calculations 
To determine the desired effect size for the primary outcome, we 
consulted our patient partners regarding the percent reduction in ex-
acerbations that they felt would motivate them to use an additional as- 
needed inhaler. Our patient partners told us that a reduction by a quarter 
in asthma exacerbation rates would be meaningful for them, and we 
powered the study accordingly. We felt that an enrollment of 1200 
participants was feasible, and thus needed to extend beyond the initially 
planned 12 months of follow-up in order to appropriately power the 
study. Thus, for the primary efficacy outcome, power calculations were 
based on an estimated primary event intensity of 0.4 exacerbations per 
year (0.5 per 15 months) in the control arm, 15 months of follow-up for 
each individual with an annualized rate of uniform loss to follow-up of 
25% (31.25% in 15 months of follow-up), and a two-sided significance 
level of 0.05. With these assumptions, 1200 participants (600 per arm) 
yielded 80% power to declare a reduction of 23.5% in the rate of ex-
acerbations as statistically significant. We did not factor adherence 
directly into the model, as this is a pragmatic study, but did inflate the 
sample size to allow for dropouts and low adherence. 
Sample size and power calculations were performed using PASS 
software [43], using the similarity of inference between the Andersen- 
Gill models and Poisson regression. 
3.3. Randomization and blinding 
Participants are centrally randomized, stratifying by site and race/ 
ethnicity (AA/B versus H/L), using the PEERS® system. Participants are 
randomized in a 1:1 ratio of intervention (PARTICS + Usual Care) to 
control (Usual Care). In keeping with the spirit of a pragmatic trial, the 
study participants and investigators are not blinded to the treatment 
assignment. However, in order to reduce selection bias, the randomi-
zation scheme is kept confidential from all investigators. The randomi-
zation scheme is generated by an unblinded statistician at DCRI and is 
implemented by an authorized party who has no involvement in the 
conduct of the study. 
3.4. Primary endpoint analysis 
The timing and frequency of asthma exacerbations during follow-up 
in the two randomized treatment arms will be compared using the 
Andersen-Gill adaptation of the time-to-event Cox proportional hazard 
model with robust standard errors to account for multiple occurrences of 
the outcome in each participant. This comparison will be stratified by 
race/ethnic group: AA/B and H/L (participants who self-identify as both 
AA/B and H/L will be classified as H/L, in accordance with our patient 
partners’ recommendation). The following baseline characteristics, 
which may influence the rate of exacerbations or the response to ICS, 
will be adjusted for in the primary analysis model: age, sex, smoking 
status, body mass index (BMI), geographic region, season of randomi-
zation, history of exacerbations in the past year, and use of ICS/LABA 
prior to randomization. 
Several secondary analyses of primary endpoint data will be per-
formed. Comparison between the two groups of the count of asthma 
exacerbations during follow-up will be performed using the Poisson 
model. If overdispersion of data is noticed, negative binomial regression 
will be used. Time from randomization to first asthma exacerbation 
between the two treatment arms will be compared using the log-rank 
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test, and survival curves will be constructed using the Kaplan-Meier 
method. Sensitivity analyses will be performed: first, to test whether 
the change of ICS from QVAR® to QVAR® RediHaler™ has a significant 
effect on the effectiveness of PARTICS; second, to evaluate the effect of 
protocol and treatment compliance by constructing and analyzing 
treatment and protocol compliance estimands; and third, using the 
modified intention-to-treat (mITT) population to analyze the primary 
endpoint. The mITT population will include all participants in the ITT 
population minus those who meet any of the following criteria: (1) did 
not have an exacerbation in the year prior to randomization and had an 
ACT score of ≥20 at enrollment; (2) were not taking ICS at enrollment; 
or (3) have COPD and did not meet the COPD inclusion criteria. 
3.5. Covariate analysis 
The heterogeneity of treatment effect among various participant 
characteristics will be studied by examining the interaction of several 
different covariates with the randomized treatment group using the 
Andersen-Gill model. These covariates are detailed in Table 4. 
The covariates that are adjusted for in the primary analysis model, 
listed above, will also be included in the models when we examine each 
interaction of interest. If the covariate of interest is already on the list of 
covariates that are included in the model, this covariate is included in 
the model only once. Covariates that will be both included in the model 
and tested for interaction with treatment are bolded in Table 4. 
Some covariates listed in Table 4 will be analyzed as continuous 
variables in the models that examine the interaction between the vari-
able and the treatment. The linearity of this interaction will be assessed 
by fitting a flexible model using a restricted cubic spline transformation 
of the continuous variable. If nonlinearity is detected, the significance of 
the interaction between the nonlinear components of the spline function 
and the treatment will then be tested. These continuous covariates will 
be used to categorize participants into subgroups only when subgroup 
data need to be graphically displayed. 
3.6. Secondary endpoint analysis 
ACT and ASUI will be analyzed as continuous variables, using mixed 
model with repeated measures (MMRM) to compare treatment effects. 
The response variable will be change in ACT score or ASUI score from 
baseline at all 15 monthly assessments, and the predictors (included as 
fixed effects) will include randomized treatment arm, continuous time of 
assessment as a linear and quadratic term, and the interactions of the 
treatment arm with the time variables. Independent random effects will 
be included for intercept and time variables. The model will adjust for all 
the covariates included in the primary analysis model. Of note, we 
present the ACT with a slight variation from the published and validated 
version in that the order of questions 3 and 4 is reversed. 
Days lost from work, school, and usual activities will be analyzed 
using Poisson or negative binomial regression models (if overdispersion 
of data is noticed), with time as an offset to account for differential 
duration of follow-up. 
4. Discussion and conclusion 
4.1. Discussion 
The design of the PCORI-funded PREPARE study was informed by 
several key factors: PCORI’s Methodology Standards, the PRECIS 
criteria for designing pragmatic clinical trials, the outcomes of the pilot 
study, and most importantly, the ongoing guidance of our collaborative 
partners and stakeholders. These include patient partners (AA/B and H/ 
L adults with asthma and/or caregivers), patient advocacy groups, 
healthcare professionals, scientific experts, professional medical soci-
eties, health policy experts, insurers, and representatives of pharma-
ceutical companies. The insights and suggestions of our collaborative 
partners will be essential to interpretation of study outcomes and 
dissemination of study results. 
A key feature of the PREPARE study is its pragmatic design, which 
will allow for real-world assessment of the efficacy of the PARTICS 
treatment strategy (Fig. 2). The study is enrolling from both primary 
care and asthma specialty practices, allows for the inclusion of many 
patients typically excluded from asthma studies (e.g., smokers) and has 
few exclusions for comorbidities, thus supporting broad applicability. 
The intervention imposes minimal burden on practice sites and requires 
minimal patient instruction. If needed, the short PARTICS instructional 
videos are readily accessible on the internet. Thus, if successful, the 
intervention could be easily implemented. 
The PARTICS strategy and the PREPARE study have received broad 
Table 4 
Planned covariate analyses.  
Parameter Analysis 
Race/ethnic group African American/Black versus Hispanic/Latinx 
Smoking status Current (has smoked within 1 year) and former 
smokers (≥10 pack-years and has not smoked 
within 1 year) versus non-smokers (≤10 pack- 
years and has not smoked within 1 year) 
Fractional exhaled nitric 
oxide (FeNO) 
High versus low FeNO at baseline, based upon two 
different thresholds [≥20 parts per billion (ppb) versus 
<20 ppb, and ≥ 30 ppb versus <30 ppb] 
Blood eosinophil count High versus low blood eosinophil count at baseline 
(≥300 cells/μL versus <300 cells/μL) 
Questionnaire modality Paper/telephone versus online (defined as ≥80% of 
monthly questionnaires completed online) 
Attitude toward ICS As a continuous variable based on the differential 
between the Necessity and Concern subscales of the 
Asthma-Specific Beliefs about Medicine Questionnaire 
(BMQ)a 
Depressive symptoms Presence of depressive symptoms [Patient Health 
Questionnaire (PHQ-2)b score ≥ 3] versus absence 
(PHQ-2 score < 3) 
Health literacy status Low/marginal versus high based on the Brief Health 
Literacy Scale (BHLS)c 
Body mass index (BMI) As a continuous variable 
Medication use at 
baseline 
ICS/LABA versus ICS 
Comorbidities Presence versus absence at baseline of heart disease, 
cancer, stroke, diabetes, chronic kidney disease, 
COPD, Human Immunodeficiency Virus (HIV)/ 
Acquired Immunodeficiency Syndrome (AIDS), and 
hypertension 
Exacerbation history Presence versus absence of an asthma 




As a continuous variable based on the short version of 
the Everyday Discrimination Scaled 
Self-reported medication 
adherence 
As a continuous variable based on the Medication 
Adherence Report Scale (MARS-5)e  
a The Asthma-Specific BMQ has 2 scales: the Necessity Scale (measures pa-
tients’ beliefs about the necessity of ICS for managing asthma) and the Concerns 
Scale (measures patients’ concerns about negative consequences of using ICS). A 
higher score on the Necessity Scale combined with a lower score on the Concerns 
scale indicates a more accepting attitude toward ICS. 
b PHQ-2 asks two questions that screen for depression. Each question has a 
score ranging from 0 to 3. The total PHQ-2 score ranges from 0 to 6, with higher 
scores indicating greater presence of depressive symptoms. 
c The BHLS consists of 3 items. The scores on items 1 and 3 range from 1 to 4; 
the score on item 2 ranges from 1 to 5. Higher scores indicate higher subjective 
health literacy. A participant is considered to have high health literacy if he/she 
receives a score of 4 on items 1 and 3, and a score of 4 or 5 on item 2. Otherwise 
the participant is considered to have low/moderate health literacy. 
d The short version of the Everyday Discrimination Scale has 5 items with each 
item’s score ranging from 1 to 6. The total score ranges from 5 to 30, with higher 
scores indicating a higher degree of perceived discrimination. 
e The MARS-5 is a 5-item questionnaire that measures patients’ self-reported 
medication adherence. Each item has a score ranging from 1 to 5. Total scores 
range from 1 to 25, with higher scores indicating higher self-reported adherence. 
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and enthusiastic stakeholder support, for several reasons. First, the 
study’s focus on AA/B and H/L patients addresses an important gap in 
asthma care: the disproportionate asthma morbidity among AA/B and 
H/L populations. In general, efforts to increase guideline-directed care 
in asthma tend to be complex and time- and resource-consuming, but 
still do not achieve substantial improvements in treatment outcomes 
[25]. Such efforts to improve asthma management have been particu-
larly challenging among AA/B and H/L populations [44,45]. The PAR-
TICS strategy is relatively easy to implement and in line with current 
patient patterns of medication use—which makes it patient- 
empowering, intuitive, provider-friendly, sustainable and scalable. 
Additionally, PARTICS has the potential to reduce total corticosteroid 
exposure by reducing the use of oral or parenteral corticosteroids 
associated with exacerbations; as this is a cause of concern for many of 
our patient partners and healthcare professional stakeholders, this 
would be a well-received outcome. Further, the PARTICS strategy offers 
an asthma management approach that reduces the clinician and patient 
resources necessary to reduce asthma morbidity (i.e., less clinician in-
struction time, less need for intensive programs to improve adherence to 
daily ICS, less cost for inhalers potentially due to less inhaler use), which 
is particularly relevant in many communities of color where resources 
may be limited. 
Lastly, the outcomes measured have importance to multiple con-
sumers and providers in the healthcare system. The primary outcome 
measure chosen for inclusion in PREPARE was carefully selected 
considering both stakeholder input and PCORI criteria. According to our 
patient partners, asthma exacerbations have dramatic adverse effects on 
their quality of life, resulting in states of health that cause distress, 
severely limit their activities, and result in loss of income or require 
personal financial expenditures. In addition, asthma exacerbations are 
associated with progressive decline in lung function [46] and cost the 
healthcare system billions of dollars annually [3,4]. Thus, the primary 
outcome measure of asthma exacerbations is of utmost importance to all 
stakeholders. The secondary outcome measures of asthma control, 
preference-based quality of life, and days lost from work or school will 
all be assessed using validated and well-documented patient-reported 
outcome measures, and reflect outcomes that our patient partners have 
indicated as important to them. 
While as-needed use of ICS is not currently approved by the United 
States Food & Drug Administration (FDA), the PREPARE stakeholders 
have explicitly and unanimously agreed that, should the PARTICS 
strategy result in reduced asthma exacerbation rates, they would sup-
port the adoption of this strategy as part of routine asthma management. 
Of note, at least one pharmaceutical company is developing a combi-
nation ICS/SABA preparation for approval in the United States. Addi-
tionally, the World Health Organization (WHO) Global INitiative for 
Asthma (GINA) 2020 asthma guidelines recommend as-needed low-dose 
ICS/formoterol (over as-needed SABA) as the preferred reliever for adult 
patients with asthma [46]. We applaud these recommendations. How-
ever, the study populations in the studies forming the basis of the GINA 
recommendations included very few individuals of color and several 
studies have suggested that AA/B and H/L populations may respond 
differently to asthma interventions [47–52]. Further, populations of 
color may have belief systems (e.g., negative beliefs about ICS [53]) and 
healthcare access which may impact the applicability of certain in-
terventions. Prior to the adoption of an as-needed ICS strategy for AA/B 
and H/L populations, a pragmatic study such as PREPARE, to demon-
strate that such an approach is applicable to these populations, is ur-
gently needed. 
There are several limitations to the PREPARE study. First, study 
participants are unblinded to their treatment assignment. While it is 
somewhat unlikely that the lack of participant blinding will have a large 
effect on exacerbations requiring steroids, it is possible that beliefs 
related to PARTICS efficacy may impact our secondary outcome mea-
sures, all of which are patient-reported. Second, the PARTICS + Usual 
Care group is provided with an additional ICS inhaler that the Usual 
Care group does not receive. Indeed, it is possible that participants in the 
PARTICS arm may use their study-provided ICS in ways other than 
intended, which could result in improvements merely related to 
increased availability of ICS. We discussed this with our healthcare 
professional and insurance partners, who agreed they would be willing 
to support the use of as-needed ICS should the study results be positive, 
despite this limitation. Further, considering the generally poor adher-
ence to ICS documented in the literature [20–23], it is unlikely that most 
of our participants would use extra ICS. Lastly, by providing ICS and 
SABA in separate canisters, it is possible that our study will underesti-
mate the effect of PARTICS due to participant non-adherence with the 
PARTICS strategy. A combination inhaler containing ICS and SABA in a 
single canister would eliminate the issue of participants forgetting to 
take their ICS each time they take their SABA; as mentioned above, 
Fig. 2. PREPARE PRECIS diagram.  
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combination ICS/SABA products are being developed for the US market. 
We recognize this issue and, as mentioned, chose to depart from strict 
PRECIS criteria for pragmatic studies by reminding PARTICS partici-
pants on a monthly basis to use their as-needed ICS and SABA together. 
By introducing these measures to improve adherence, we reduced the 
pragmatic nature of the PREPARE trial protocol with regards to the 
flexibility of the intervention. However, we felt that deviating from the 
PRECIS pragmatic design in order to reinforce using ICS with SABA 
made sense and was acceptable given the impending availability of a 
combination ICS/SABA inhaler in the United States. 
4.2. Conclusion 
In summary, PREPARE is a 15-month pragmatic, randomized, 
parallel-group study of a patient-centered asthma intervention in patient 
populations that suffer disproportionately from asthma morbidity and 
mortality. We are enrolling 1200 adult AA/B and H/L patients and 
assessing whether the PARTICS strategy, when added on to usual care, 
can reduce deleterious asthma outcomes of great concern to patients and 
other stakeholders. The design of this study has been heavily informed 
by A/A and H/L patient partners, patient advocates, and other key 
stakeholders in healthcare, while also meeting the rigorous re-
quirements of PCORI-funded research and aligning as much as possible 
with PRECIS criteria for a pragmatic clinical trial. Outcomes of this 
study have the potential to offer powerful evidence supporting PARTICS 
as an effective asthma management strategy for reducing morbidity in 
these populations. 
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